详细说明
- Purity>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
- Endotoxin Level<0.10 EU per 1 μg of the protein by the LAL method.
- ActivityMeasured by the ability of the immobilized protein to support the adhesion of the L Cells mouse fibroblast cell line. The ED 50 for this effect is 0.4-2.4 μg/mL
- SourceHuman embryonic kidney cell, HEK293-derived
Human CEACAM-19
(Ala33-Gly157)
Accession # Q7Z692-1IEGRMD Human IgG1
(Pro100-Lys330)N-terminus C-terminus - Accession #
- N-terminal Sequence
AnalysisAla33 - Structure / FormDisulfide-linked homodimer
- Predicted Molecular Mass40 kDa
- SDS-PAGE42-56 kDa, reducing conditions
| 9397-CM | | |
| Formulation Lyophilized from a 0.2 μm filtered solution in PBS. | ||
| Reconstitution Reconstitute at 500 μg/mL in PBS. | ||
| Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. | ||
| Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Data Images
| Bioactivity | Immobilized Recombinant Human CEACAM-19 (Catalog # 9397-CM)enhances L Cells mouse fibroblasts adhesion. The ED50 for this effect is 0.4-2.4 μg/mL. |
Background: CEACAM-19
Carcinoembryonic antigen-related cell adhesion molecule-19 (CEACAM-19), also known as CEA-like gene 1 (CEAL1), is a member of the CEACAM subfamily of glycoproteins in the immunoglobulin (Ig) superfamily. Mature human CEACAM-19 consists of a 125 amino acid (aa) extracellular domain, a 21 aa helical transmembrane domain, and a 122 aa cytoplasmic domain (1,2). The extracellular domain contains an Ig-like domain as well as a glycosylation site, while the cytoplasmic domain is predicted to contain at least one immunoreceptor tyrosine-based activation motif (ITAM) (3,4). The extracellular domain of human CEACAM-19 shows 71%, 72%, and 78% aa identity to mouse, rat, and bovine CEACAM-19. The CEACAM family of proteins are involved in numerous intercellular-adhesion and intracellular signaling processes including cell adhesion, cell growth, recognition and differentiation, angiogenesis, and apoptosis (5,6). CEACAM-19 expression has been identified in a wide range of tissues including prostate, uterus, fetal brain, mammary and adrenal glands, skeletal muscle, small intestine, and kidney (1). Human CEACAM-19 has been found to be overexpressed in BT-474, BT20, and T47D breast cancer cell lines as well as LNCaP prostate cancer cells, suggesting a role in tumor progression and metastasis (1,3, 7). The overexpression in breast cancer patients is associated with poor prognosis (7).
- References:
- Schorilas, A. et al. (2003) Gene 310:79.
- Estiar, M. et al. (2016) Clin Exp Med doi:10.1007/s10238-016-0442-1.
- Beauchemin, N. and Arabzadeh, A. (2013) Cancer Metastasis Rev 32 (3-4):643.
- Kuespert, K. et al. (2006) Curr Opin Cell Biol 18:565.
- Obrink, B. (1997) Curr Opin Cell Biol 9:616.
- Horst, AK. and Wagener, C. (2004) Handb Exp Pharmacol 283.
- Michaelidou, K. et al. (2013) Int J Oncol 42:1770.
- Long Name:Carcinoembryonic Antigen-related Cell Adhesion Molecule 19
- Entrez Gene IDs:56971 (Human); 319930 (Mouse); 680640 (Rat)
- Alternate Names:carcinoembryonic antigen-related cell adhesion molecule 19; CEACAM19; CEACAM-19; CEAL1
400-6226-992